Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome - PubMed
3 hours ago
- #IL-17
- #Metabolic Syndrome
- #Psoriasis
- Psoriasis is a systemic inflammatory disease linked to cardiometabolic comorbidities like obesity and type 2 diabetes.
- The IL-17 axis is central to driving both skin inflammation in psoriasis and systemic metabolic dysfunction.
- IL-17, along with cytokines and adipokines, contributes to insulin resistance and adipose tissue inflammation.
- IL-17 pathway is involved in the 'psoriatic march,' connecting chronic inflammation to accelerated atherosclerosis.
- IL-17 inhibitors are effective for psoriasis treatment and may have beneficial effects on cardiometabolic markers.